Philippe Boutet

Waver, VLG 1300, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.

Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.

Journal: Human vaccines & immunotherapeutics

Published: August 26, 2026

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Journal: Human vaccines & immunotherapeutics

Published: October 18, 2024

Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.

Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.

Journal: Vaccines

Published: October 05, 2022

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Journal: NPJ vaccines

Published: November 14, 2021

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.

Journal: Nature communications

Published: October 28, 2021

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets.

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets.

Journal: NPJ vaccines

Published: September 06, 2020

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost.

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost.

Journal: NPJ vaccines

Published: December 13, 2018

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.

Journal: Human vaccines & immunotherapeutics

Published: November 27, 2014

Vaccine for prevention of mild and moderate-to-severe influenza in children.

Vaccine for prevention of mild and moderate-to-severe influenza in children.

Journal: The New England journal of medicine

Published: December 17, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026